Shares of pharmaceutical companies fell across Europe and Asia after President Donald Trump said he planned to order a cut in ...

Takeda Pharmaceuticals delivered strong FY2024 results and offers value with a 4.81% yield, despite pressure from Vyvanse ...

Takeda was scrambling to accommodate for rapidly sinking profits from the hasty decline of ADHD mainstay Vyvanse with a 140 ...

Takeda will be investing approximately $30 billion into its U.S. operations over the next five years, the company announced.

Takeda will host an investor call on Sunday ... but it is to illustrate that as a global innovative pharmaceutical company, we have a very strong presence in the U.S., which is, by far today ...

TOKYO -- Japanese drugmaker Takeda Pharmaceuticals will invest $30 billion in the U.S. over the next five years, CEO ...

Takeda’s Julie Kim argues that Trump’s idea to match drug prices to that of other countries could cost the industry up to $1 ...

Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for Takeda Pharmaceutical Co. imply an improvement in the company's underlying business. Investors should show ...

Texas grocer H-E-B, along with Kroger, Albertsons and Walgreen Co., is accusing pharmaceutical companies of hurting competition. A recently filed lawsuit alleges Japanese drug maker Takeda ...

Takedas dengue vaccine Qdenga is set to launch in India by 2026 through a partnership with Biological E offering hope against rising dengue cases with local production and global backing ...